Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 5 of 5 clinical reviews.
Semaglutide 2.4 mg produces smaller absolute weight loss in East Asian patients than in White populations, but relative metabolic benefit may be equivalent or greater. Learn why BMI thresholds, pharmacogenomics, and trial design all matter.
Read clinical reviewA clinician-focused review of semaglutide 2.4 mg dosing in East Asian patients, covering pharmacogenomics, BMI thresholds, ethnicity-stratified trial data, and practical titration guidance.
Read clinical reviewA clinical deep-dive into semaglutide 2.4 mg dosing for Hispanic and Latino patients, covering ethnicity-stratified STEP trial subgroups, pharmacogenomics, insulin resistance phenotypes, and practical titration guidance.
Read clinical reviewSouth Asian patients using Wegovy (semaglutide 2.4 mg) may see smaller percentage weight loss than trial averages suggest. Here is what ethnicity-stratified subgroup data, pharmacogenomic research, and revised BMI thresholds tell clinicians and patients.
Read clinical reviewEvidence-based guide to Wegovy (semaglutide 2.4 mg) dosing considerations for South Asian patients, including BMI thresholds, pharmacogenomic factors, and titration guidance.
Read clinical review